Ovarian Cancer Clinical Trial

Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors

Summary

The present investigation will prospectively evaluate whether serial transvaginal ultrasonography with Morphology Index (MI) can further reduce false positive results by more accurately distinguishing benign from malignant ovarian tumors. If there is no change in the detection of true positive cases, the result will be an increase in the positive predictive value of ovarian cancer screening.

View Full Description

Full Description

Primary Objective:

To determine if a treatment algorithm using serial transvaginal ultrasound with a tumor morphology index can improve the positive predictive value (PPV) of ovarian cancer screening compared to a historical control from 15% to 25%.

Secondary Objective To measure the compliance for study participants enrolled on the treatment algorithm using serial transvaginal ultrasound with a tumor morphology index.

Exploratory Objective To determine the effectiveness of a treatment algorithm that combines serum biomarkers aloneor in combination with transvaginal ultrasound to reduce the false positive rate of ovarian cancer screening in the subset of women agreeing to biomarker collection.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Women must be enrolled in the University of Kentucky Ovarian Cancer Screening Program Eligibility criteria for the OCSP are: 50 years of age or older, or be postmenopausal and have not had a prior salpingo-oophorectomy or have a family history of ovarian cancer in a primary relative or have a self-history of breast cancer.
Patients have a documented ovarian abnormality on ultrasound
Patients having undergone prior hysterectomy will be eligible provided that they meet the other requirements for entry into this study.
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

Patients who are not enrolled in the University of Kentucky Ovarian Cancer Screening Program .
Patients who cannot tolerate the vaginal ultrasound procedure.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Patients who are referred with pelvic symptoms, a known pelvic mass, or a history of prior radiation, will be excluded from this investigation.
History of ovarian cancer.
Prior bilateral salpingo-oophorectomy.
Prisoners.
Women who are currently pregnant.

Study is for people with:

Ovarian Cancer

Estimated Enrollment:

3290

Study ID:

NCT02227654

Recruitment Status:

Recruiting

Sponsor:

Frederick R. Ueland, M.D.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Markey Cancer Center, University of Kentucky
Lexington Kentucky, 40536, United States More Info
Frederick R. Ueland, M.D.
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Estimated Enrollment:

3290

Study ID:

NCT02227654

Recruitment Status:

Recruiting

Sponsor:


Frederick R. Ueland, M.D.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.